van Berkel J, Lalieu R C, Joseph D, Hellemons M, Lansdorp C A
Eurocept Clinics, Amersfoort/Rotterdam, The Netherlands.
Hyperbaric Medical Center (HGC), Rijswijk, The Netherlands.
Sci Rep. 2025 Aug 4;15(1):28351. doi: 10.1038/s41598-025-11539-0.
A potential beneficial effect of hyperbaric oxygen therapy (HBOT) on complaints of long COVID was found, leading to increased demand for this treatment despite many remaining clinical questions and lack of formal guideline recommendations and reimbursement. A registry was set up in order to gain more insight into patient characteristics and (long-term) outcomes of long COVID patients undergoing HBOT. Patient-reported outcome measures were collected at baseline, after treatment, at 3-month and 1-year follow up. This publication includes the 3-month results. The primary outcome measures were the mental and physical component score (MCS/PCS) of the SF-36 questionnaire. A clinically relevant positive or negative response was defined as a ≥ 10 point increase or decrease of in MCS and/or PCS after 3 months. Secondary outcomes included the EQ-5D, severity of complaints and ability to work. In this prospective registry, 56-63% of long term-ill patients had a clinically relevant improvement in MCS/PCS 3 months after HBOT. However, 13-19% of the patients had a clinically relevant deterioration in MCS/PCS. Symptoms that showed most improvement were predominantly in the cognitive domain. This indicates that HBOT may have a positive effect on complaints of long COVID, but alertness for worsening of the condition should be exercised.
人们发现高压氧疗法（HBOT）对长期新冠症状可能有有益效果，尽管仍存在许多临床问题，且缺乏正式的指南建议和报销政策，但这导致了对该疗法需求的增加。为了更深入了解接受HBOT治疗的长期新冠患者的特征和（长期）预后，设立了一个登记处。在基线、治疗后、3个月和1年随访时收集患者报告的结局指标。本出版物包括3个月的结果。主要结局指标是SF-36问卷的心理和生理成分得分（MCS/PCS）。临床相关的阳性或阴性反应定义为3个月后MCS和/或PCS增加或减少≥10分。次要结局包括EQ-5D、症状严重程度和工作能力。在这个前瞻性登记处中，56-63%的长期患病患者在接受HBOT治疗3个月后MCS/PCS有临床相关改善。然而，13-19%的患者MCS/PCS有临床相关恶化。改善最明显的症状主要在认知领域。这表明HBOT可能对长期新冠症状有积极作用，但应警惕病情恶化。
